Literature DB >> 34716836

Sarcopenia as a Predictor of Survival in Patients with Pancreatic Adenocarcinoma After Pancreatectomy.

Hadass Rom1,2, Shlomit Tamir3,2, Jeroen L A Van Vugt4, Yael Berger1,2, Gali Perl5, Sara Morgenstern6, Ana Tovar6, Baruch Brenner5, Daniel Benchimol1, Hanoch Kashtan1,2, Eran Sadot7,8.   

Abstract

OBJECTIVE: To determine whether sarcopenia can potentially predict worse survival after resection of pancreatic ductal adenocarcinoma.
BACKGROUND: Sarcopenia is correlated with poor outcomes in hepatopancreatobiliary malignancies, but the relationship of both its qualitative and quantitative features with patient survival after pancreatectomy has not been investigated in a western population. PATIENTS AND METHODS: Preoperative cross-sectional computed tomography scans of consecutive patients who underwent pancreatectomy in 2005-2017 were evaluated for skeletal muscle index (SMI), intramuscular adipose tissue content (IMAC), and visceral-to-subcutaneous adipose tissue area ratio (VSR). Sex-specific categorical cut-offs were determined. Findings were correlated with outcome.
RESULTS: The study included 111 patients, 47% of whom were female, with a median age of 67 years (range: 35-87 years), and median body mass index of 23 kg/m2 (range: 16-40 kg/m2); 77% had a Whipple procedure and 66% received adjuvant chemotherapy. Low SMI correlated with poor overall survival (OS) (P = 0.007), disease-specific survival (DSS) (P = 0.006), and recurrence-free survival (RFS) (P = 0.01). High IMAC correlated with poor OS (P = 0.04). Patients with high IMAC tended to have a shorter DSS (P = 0.09), with no correlation with RFS (P = 0.6). VSR was not associated with survival. Multivariable analysis yielded an independent association of low SMI with OS (HR = 1.7, 95%CI: 1.1-2.8, P = 0.02), DSS (HR = 1.8, 95%CI: 1.03-3.2, P = 0.04), and RFS (HR = 1.8, 95%CI: 1.1-2.8, P = 0.01), and of high IMAC with OS (HR = 1.9, 95%CI: 1.1-3.1, P = 0.01).
CONCLUSION: Both qualitative and quantitative measures of skeletal muscle were independently associated with impaired survival in patients with resectable PDAC. Sarcopenia might serve as an early radiographic surrogate of aggressive tumor behavior, with potential implications for clinical decision-making and future study.
© 2021. Society of Surgical Oncology.

Entities:  

Keywords:  Intramuscular adipose tissue; Pancreatectomy; Pancreatic ductal adenocarcinoma; Sarcopenia; Skeletal muscle; Survival; Visceral adipose tissue subcutaneous adipose tissue

Mesh:

Year:  2021        PMID: 34716836     DOI: 10.1245/s10434-021-10995-y

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  34 in total

1.  Risk of morbidity and mortality following hepato-pancreato-biliary surgery.

Authors:  Peter J Kneuertz; Henry A Pitt; Karl Y Bilimoria; Jill P Smiley; Mark E Cohen; Clifford Y Ko; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2012-07-04       Impact factor: 3.452

2.  Total pancreatectomy for pancreatic adenocarcinoma: evaluation of morbidity and long-term survival.

Authors:  Sushanth Reddy; Christopher L Wolfgang; John L Cameron; Frederic Eckhauser; Michael A Choti; Richard D Schulick; Barish H Edil; Timothy M Pawlik
Journal:  Ann Surg       Date:  2009-08       Impact factor: 12.969

3.  Follow-up Computed Tomography after Evacuation of Chronic Subdural Hematoma.

Authors:  Philippe Schucht; Urs Fischer; Christian Fung; Corrado Bernasconi; Jens Fichtner; Sonja Vulcu; Daniel Schöni; Andreas Nowacki; Stefan Wanderer; Christian Eisenring; Anna K Krähenbühl; Heinrich P Mattle; Marcel Arnold; Nicole Söll; Lucas Tochtermann; Werner Z'Graggen; Stefanie T Jünger; Jan Gralla; Pasquale Mordasini; F Michael Dahlweid; Andreas Raabe; Jürgen Beck
Journal:  N Engl J Med       Date:  2019-03-21       Impact factor: 91.245

4.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.

Authors:  Lola Rahib; Benjamin D Smith; Rhonda Aizenberg; Allison B Rosenzweig; Julie M Fleshman; Lynn M Matrisian
Journal:  Cancer Res       Date:  2014-06-01       Impact factor: 12.701

5.  Perioperative outcomes and long-term quality of life after total pancreatectomy.

Authors:  A Pulvirenti; A Pea; N Rezaee; C Gasparini; G Malleo; M J Weiss; J L Cameron; C L Wolfgang; J He; R Salvia
Journal:  Br J Surg       Date:  2019-07-08       Impact factor: 6.939

6.  Induction of antibody tolerance to sheep erythrocytes in lizards using modified erythrocyte preparations.

Authors:  S Baskar; V Muthukkaruppan
Journal:  Dev Comp Immunol       Date:  1980       Impact factor: 3.636

Review 7.  Cancer-associated malnutrition, cachexia and sarcopenia: the skeleton in the hospital closet 40 years later.

Authors:  Aoife M Ryan; Derek G Power; Louise Daly; Samantha J Cushen; Ēadaoin Ní Bhuachalla; Carla M Prado
Journal:  Proc Nutr Soc       Date:  2016-01-20       Impact factor: 6.297

Review 8.  Iron therapy in anaemic adults without chronic kidney disease.

Authors:  Kurinchi Selvan Gurusamy; Myura Nagendran; Jack F Broadhurst; Stefan D Anker; Toby Richards
Journal:  Cochrane Database Syst Rev       Date:  2014-12-31

9.  Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

Authors:  Alok A Khorana; Pamela B Mangu; Jordan Berlin; Anitra Engebretson; Theodore S Hong; Anirban Maitra; Supriya G Mohile; Matthew Mumber; Richard Schulick; Marc Shapiro; Susan Urba; Herbert J Zeh; Matthew H G Katz
Journal:  J Clin Oncol       Date:  2017-04-11       Impact factor: 44.544

10.  Aggressive surgery for borderline resectable pancreatic cancer: evaluation of National Comprehensive Cancer Network guidelines.

Authors:  Suguru Yamada; Tsutomu Fujii; Hiroyuki Sugimoto; Shuji Nomoto; Shin Takeda; Yasuhiro Kodera; Akimasa Nakao
Journal:  Pancreas       Date:  2013-08       Impact factor: 3.327

View more
  2 in total

1.  Prognostic value of computed tomography derived skeletal muscle mass index in lung cancer: A meta-analysis.

Authors:  Xue-Lin Pan; Hong-Jun Li; Zhen Li; Zhen-Lin Li
Journal:  World J Clin Cases       Date:  2022-07-16       Impact factor: 1.534

2.  Who could complete and benefit from the adjuvant chemotherapy regarding pancreatic ductal adenocarcinoma? A multivariate-adjusted analysis at the pre-adjuvant chemotherapy timing.

Authors:  Ningzhen Fu; Kai Qin; Jingfeng Li; Jiabin Jin; Yu Jiang; Xiaxing Deng; Baiyong Shen
Journal:  Cancer Med       Date:  2022-04-17       Impact factor: 4.711

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.